HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nobutoshi Morimoto Selected Research

Telmisartan (Micardis)

4/2015Long-term effect of telmisartan on Alzheimer's amyloid genesis in SHR-SR after tMCAO.
11/2014Telmisartan reduces progressive accumulation of cellular amyloid beta and phosphorylated tau with inflammatory responses in aged spontaneously hypertensive stroke resistant rat.
10/2014Strong improvement of apolipoprotein E/low-density lipoprotein receptor signals by telmisartan in poststroke spontaneously hypertensive stroke resistant.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Nobutoshi Morimoto Research Topics

Disease

9Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
08/2013 - 10/2008
6Alzheimer Disease (Alzheimer's Disease)
04/2015 - 08/2007
5Stroke (Strokes)
04/2015 - 04/2013
5Amyloid Plaque
04/2015 - 01/2011
4Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
04/2015 - 08/2010
3Cognitive Dysfunction
01/2019 - 01/2011
3Neuroinflammatory Diseases
04/2015 - 01/2011
2Parkinson Disease (Parkinson's Disease)
01/2021 - 06/2010
2Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
01/2020 - 11/2019
2Polyneuropathies (Polyneuropathy)
01/2020 - 11/2019
2Hypertension (High Blood Pressure)
04/2015 - 11/2014
2Metabolic Syndrome (Dysmetabolic Syndrome X)
11/2014 - 10/2014
2Brain Ischemia (Cerebral Ischemia)
10/2014 - 08/2010
2Ischemic Stroke
10/2013 - 04/2013
2Hypoxia (Hypoxemia)
02/2013 - 09/2012
2Transient Ischemic Attack
06/2012 - 05/2012
2Infarction (Infarctions)
08/2010 - 01/2008
1Status Epilepticus (Complex Partial Status Epilepticus)
05/2022
1Wernicke Encephalopathy (Wernicke's Encephalopathy)
05/2022
1Poisoning
01/2022
1Acidosis
01/2022
1Meningitis
02/2020
1Cryptococcal Meningitis
02/2020
1Deglutition Disorders (Dysphagia)
09/2019
1Hepatitis C
09/2019
1Infections
09/2019
1Quadriplegia (Spastic Quadriplegia)
09/2019
1Inclusion Body Myositis
09/2019
1Chronic Hepatitis C
09/2019
1Dementia (Dementias)
10/2014
1Liposarcoma
09/2013
1Spinocerebellar Ataxias (Spinocerebellar Ataxia)
09/2013
1Sarcoma (Soft Tissue Sarcoma)
09/2013
1Embolism (Embolus)
04/2013
1Cerebral Hemorrhage
04/2013
1Inflammation (Inflammations)
07/2012
1Autosomal Dominant Optic Atrophy (Dominant Optic Atrophy)
06/2012

Drug/Important Bio-Agent (IBA)

12Proteins (Proteins, Gene)FDA Link
11/2019 - 10/2008
4Superoxide Dismutase-1IBA
02/2013 - 10/2008
3Amyloid (Amyloid Fibrils)IBA
04/2015 - 01/2011
3Telmisartan (Micardis)FDA Link
04/2015 - 10/2014
3CholesterolIBA
10/2014 - 01/2011
3pitavastatin (itavastatin)FDA Link
03/2013 - 01/2011
3Atorvastatin (Lipitor)FDA Link
03/2013 - 01/2011
3Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
11/2012 - 01/2011
2Immunoglobulin G (IgG)IBA
01/2020 - 11/2019
2Granulocyte Colony-Stimulating Factor (G-CSF)IBA
11/2019 - 01/2011
2Neuroprotective AgentsIBA
11/2014 - 08/2010
2Apolipoproteins E (ApoE)IBA
10/2014 - 03/2013
2LDL Receptors (LDL Receptor)IBA
10/2014 - 03/2013
2Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA
10/2014 - 11/2010
2oxidized low density lipoproteinIBA
10/2014 - 03/2013
2ApolipoproteinsIBA
10/2014 - 03/2013
2EdaravoneIBA
10/2013 - 04/2013
2Tissue Plasminogen Activator (Alteplase)FDA Link
10/2013 - 04/2013
2LipidsIBA
11/2012 - 01/2011
1Bromisovalum (Bromisoval)IBA
05/2022
1Ethylene Glycol (Monoethylene Glycol)IBA
01/2022
1Calcium OxalateIBA
01/2022
1Phosphoric Monoester Hydrolases (Phosphatases)IBA
01/2021
1TensinsIBA
01/2021
1Phosphotransferases (Kinase)IBA
01/2021
1AntigensIBA
02/2020
1Adrenal Cortex Hormones (Corticosteroids)IBA
02/2020
1HLA-DRB1 Chains (HLA DRB1)IBA
01/2020
1HLA Antigens (Human Leukocyte Antigens)IBA
01/2020
1Interleukin-4 (Interleukin 4)IBA
11/2019
1AntibodiesIBA
11/2019
1Interleukin-13IBA
11/2019
1Chemokine CCL5IBA
11/2019
1Interleukin-10 (Interleukin 10)IBA
11/2019
1CytokinesIBA
11/2019
1ChemokinesIBA
11/2019
1Interleukin-6 (Interleukin 6)IBA
11/2019
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
11/2019
1Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link
11/2019
1AutoantibodiesIBA
09/2019
1paritaprevirIBA
09/2019
1ombitasvirIBA
09/2019
15'-Nucleotidase (5' Nucleotidase)IBA
09/2019
1Intravenous Immunoglobulins (IVIG)FDA Link
09/2019
1Ritonavir (Norvir)FDA Link
09/2019
1Twendee XIBA
01/2019
1Angiotensin II Type 1 Receptor BlockersIBA
04/2015
1Amyloid beta-PeptidesIBA
11/2014
1SolutionsIBA
10/2014
1Angiotensin Receptor AntagonistsIBA
10/2014
1Nuclear Proteins (Protein, Nuclear)IBA
09/2013
1Warfarin (Coumadin)FDA LinkGeneric
04/2013
1Advanced Glycation End ProductsIBA
03/2013
1LeptinIBA
03/2013
1Insulin ReceptorIBA
03/2013
1AdiponectinIBA
03/2013
1Heat Shock Transcription FactorsIBA
12/2012
1Dynamins (Dynamin)IBA
06/2012
1mitochondrial transcription factor AIBA
06/2012

Therapy/Procedure

3Therapeutics
09/2019 - 10/2008
1Immunotherapy
11/2019
1Aftercare (After-Treatment)
09/2019
1Thrombolytic Therapy
04/2013